Pharma

us-fda-panel-s-opinion-was-somewhat-at-odds-with-the-agency-s-own-scientists-who-issued-a-negative-review-of-the-merck-drug

FDA votes +ve for Merck drug despite glitches in trial data

  • US
  • |
  • Regulatory

Singapore: An US FDA panel has voted that Merck & Co experimental insomnia drug appears to be safe and effective, despite evidence from company trials that the pill can cause daytime sleepiness and difficulty driving. The FDA is not obligated... Read more

johnson-johnson-launched-11-new-products-since-2009-which-have-raked-in-17-percent-of-its-total-pharma-sales-last-year

J&J to seek nod for 11 new drugs by 2017


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Johnson & Johnson (J&J) revealed that it is aiming to apply for approval of 10 new drugs in the US and Europe,... Read more

one-third-of-ranbaxy-s-14-600-global-sales-staff-may-lose-their-jobs

Ranbaxy may fire 1/3rd of its global sales staff


  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ranbaxy Laboratories is contemplating on slashing its global sales staff by about a third, with a majority of... Read more

daiichi-may-take-legal-action-against-former-shareholders-of-ranbaxy-as-it-believes-that-they-concealed-and-misrepresented-critical-information-concerning-the-us-department-of-justice-doj-and-us-fda-inves

Daiichi may take legal action against ex-Ranbaxy promoters

  • Japan
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Breaking its silence for the first time in 10 days after Indian drug major Ranbaxy's $500 million settlement of the US Food and... Read more

ranbaxy-reflects-on-the-its-actions-that-it-been-taking-in-recent-years-to-ensure-the-safety-and-efficacy-of-all-its-products

Ranbaxy reflects on steps taken for product safety

  • India
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Ranbaxy Laboratories highlighted some of the major specific actions the company has been taking in recent years to address certain... Read more

axway-will-help-sanofi-ensure-that-all-divisions-subsidiaries-and-new-acquisitions-are-able-to-efficiently-and-securely-exchange-and-manage-data-in-a-way-that-is-uniform-globally

Axway helps Sanofi to ‘fool-proof’ its IT infrastructure

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Sanofi joined hands with Axway in order to streamline processes and transform its technology infrastructure into an efficient... Read more

winners-of-glaxosmithkline-gsk-discovery-fast-track-competition-will-partner-with-investigators-on-gsk-s-discovery-partnerships-with-academia-dpac-team

GSK launches discovery competition for researchers

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: GlaxoSmithKline (GSK) launched Discovery Fast Track, a competition designed to accelerate the translation of academic research... Read more

pfizer-stops-its-phase-iii-study-of-inotuzumab-ozogamicin

Pfizer halts 'useless' phase III lymphoma study

  • US
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Pfizer has discontinued its phase III randomized, open-label, two-arm study (B1931008) evaluating the safety and efficacy of... Read more

alchemia-provides-update-on-fondaparinux-its-new-collaboration-with-merck-serono-and-its-current-ha-irinotecan-phase-iii-clinical-trial

Alchemia provides update on its core projects

  • Australia
  • |
  • Company Results
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: Australia-based Alchemia has provided commercial update on four of its key projects, including its marketed drug fondaparinux;... Read more

globaldata-report-japan-s-branded-hronic-myeloid-leukemia-cml-therapeutics-market-will-grow-to-usd565-million-in-2022-at-a-cagr-of-1

Japan leukemia market to grow to $565mn in 2022

  • Japan
  • |
  • Analysis
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: A new study by research and consulting firm GlobalData, highlighted that Japan's chronic myeloid leukemia (CML) market is going... Read more

astrazeneca-s-new-usd500-million-headquarters-will-be-located-at-the-south-of-cambridge

AstraZeneca to move HQ to $500 mn home in Cambridge

  • Europe
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: AstraZeneca is looking to move its research and global headquarters to Cambridge, UK, and has zeroed in on a site located at... Read more

amgen-beta-pharmaceuticals-will-bring-colon-cancer-drug-vectibix-to-the-chinese-market

Amgen forms JV to launch cancer drug in China

  • China
  • |
  • News
  • |
  • By BioSpectrum Bureau
  • |
  • 0 Comment

Singapore: US-based Amgen is going to enter into a joint venture with Chinese pharmaceutical firm Zhejiang Beta Pharma, in which Amgen will... Read more

Previous 1 3 4 5 6 7

Special Features

Survey Box

Ranbaxy Controversy

Will the Ranbaxy controversy end the Indian pharma dominion in the US market?

Send this article by email

X